HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese

Dinh Van Nguyen1,2,3,4, Hieu Chi Chu2,†, Doan Van Nguyen1,2, Minh Hong Phan4, Timothy Craig5, Karl Baumgart6, and Sheryl van Nunen3

1Department of Allergy and Clinical Immunology, Hanoi Medical University, Hanoi 10000, Vietnam
2Center of Allergology and Clinical Immunology, Bach Mai Hospital, Hanoi 844, Vietnam
3Department of Allergy and Clinical Immunology, Royal North Shore Hospital and Sydney Medical School-Northern, The University of Sydney, Sydney, NSW 2065, Australia
4Outpatients Department, Bach Mai Hospital, Hanoi 844, Vietnam
5Section of Allergy, Asthma and Immunology, Penn State University, Hershey, PA 17033, USA
6Sonic Clinical Institute, Macquarie Park, Sydney, NSW 2113, Australia

Background: In Vietnam, we observed a high incidence of carbamazepine (CBZ)-induced severe cutaneous adverse drug reactions (SCARs)—Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), and drug-induced hypersensitivity rash with eosinophilia and systemic symptoms (DRESS). In other Asian countries, HLA-B*1502 is an established risk factor for SCARs.

Objective: The aim of our study was to determine the frequency of HLA-B*1502 in SCARs patients at a large University Medical Center in Hanoi, Vietnam.

Methods: Thirty-eight cases of SCARs caused by CBZ and 25 patients with epilepsy tolerating CBZ were enrolled in a case-controlled study. Clinical manifestations and laboratory findings were recorded for each subject. Genomic DNA was isolated using the QIAamp DNA purification system. The combination of polymerase chain reaction and sequence specific oligonucleotide probes with the Luminex 100xMAP flow cytometry dual laser system was then used to quantitate fluorescently labelled oligonucleotides attached to colour-coded microbeads.

Results: Cases comprised 20 SJS (52.6%), 7 TEN (18.4%), 8 overlap syndrome (21.1%), and 3 DRESS patients (7.9%). A strong association between HLA B*1502 and bullous skin reactions such as SJS/TEN and overlap was confirmed with an odds ratio (OR) of 33.78 (95% confidence interval [CI], 7.55–151.03), p < 0.0001, Sensitivity 91.4%, Specificity 76.0%, positive predictive value 84.2%, and negative predictive value 86.4%. We did not, however, observe any correlation between the presence of this allele and CBZ-induced nonbullous skin reactions (DRESS) (OR, 6.33; 95% CI, 0.48–82.74; p = 0.1592).

Conclusion: Our results indicate the presence of HLA-B*1502 in Vietnamese is a pharmacogenetic risk factor for developing CBZ-induced SJS/TEN.

Key words: HLA-B antigens; Carbamazepine; Drug-related side effects and adverse reactions; Pharmacogenomics

Correspondence: Dinh Van Nguyen
Department of Allergy and Clinical Immunology, Hanoi Medical University & Bach Mai Hospital, Hanoi, Vietnam & Sydney Medical School - Northern, The University of Sydney, Sydney, NSW 2065, Australia
Tel: +61-294631634
Fax: +61-294631044
E-mail: vngu3162@uni.sydney.edu.au

†Dinh Van Nguyen and Hieu Chi Chu contributed equally to this article.

http://apallergy.org

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: March 6, 2015
Accepted: April 1, 2015
INTRODUCTION
The use of carbamazepine (CBZ), a common medication employed for seizure prophylaxis and multiple other neurologically based disorders, has been confirmed to be associated with severe cutaneous adverse drug reactions (SCARs) such as Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and drug-induced hypersensitivity syndrome with rash, eosinophilia and systemic symptoms (DRESS). Data from the medical literature suggest a strong genetic predisposition to CBZ-induced adverse events in certain Asian populations possessing the HLA-B*1502 allele [1, 2]. For example, for an association between HLA-B*1502 and CBZ-induced SCARs in the Han Chinese, there is a 100% sensitivity and 97% specificity, with a 7.7% positive predictive value and 100% negative predictive value for CBZ-induced rash, with an odds ratio (OR) of 2,504 (95% confidence interval [CI], 126–49,522) [3, 4]. These findings have been replicated in extended cohorts of subjects of Chinese descent originating from separate geographic areas of China [5-8] (including Hong Kong [9]). In addition, Tassaneeyakul et al. [10] reported similar results in Thai patients, with possession of HLA-B*1502 conferring an OR of 54.76 (95% CI, 14.62–205.13) for CBZ-induced SJS/TEN. In other countries in Asia, including India [11], Malaysia [12] and Singapore [13, 14], CBZ is also a known cause of SJS/TEN. In contrast, such an association has not been demonstrated in Japanese [15] or Korean populations [4, 16, 17].

The risk of CBZ-induced SJS/TEN has not yet been determined in Vietnam, but with a documented 13.5% of people in Vietnam possessing the HLA-B*1502 allele [18], Vietnamese are probably at a high risk for CBZ-induced SCARs. In Vietnam, CBZ is utilized for epilepsy, trigeminal neuralgia, sleep disorders and various other neurologically based disorders (headache and muscular tics). It is not known whether the high incidence of SJS/TEN is secondary to the widespread use of CBZ or due to a high incidence of adverse effects to the drug CBZ. It is important to determine this risk since hypersensitivity reactions to CBZ are often life-threatening and result in significant morbidity from overlapping SJS, TEN and DRESS [19, 20]. If an association between HLA and CBZ hypersensitivity exists, a preventive program of HLA screening before administering CBZ, similar to programs in Taiwan [21] and in the United States [22], may reduce CBZ-induced SCARs morbidity and mortality in Vietnamese patients. A case-controlled study was therefore designed to determine the frequency of HLA-B*1502 in SCARs patients at a large teaching hospital in Hanoi—Bach Mai Hospital, Vietnam.

MATERIALS AND METHODS

Subjects
The study was conducted at the Center of Allergology and Clinical Immunology, Bach Mai Hospital between 2011 and 2013. There were a total of 63 participants divided into two groups (38 patients with SCARs and 25 controls). A survey instrument, focused on the history of the presenting illness, ethnicity, family history, medication usage, past medical history, any history of drug allergy and rashes, review of symptoms and physical examination, was developed. Severity-of-illness score for toxic epidermal necrolysis (SCORTEN) was applied for severity assessment [23]. SCORTEN has been defined as seven criteria including age (>40 years), heart rate (>120 beats/min), presence of malignancy, skin detachment (>10% body surface area [BSA]), serum urea level (>10 mmol/L), serum bicarbonate level (<20 mmol/L), and serum glucose level (>14 mmol/L). Maximum severity score is 7. All patients had their diagnosis of CBZ-induced SJS/TENS/DRESS confirmed by either a dermatologist or an allergologist based on the clinical morphology of the “rash” according to Roujeau [24]. Medication-induced rash was considered to have occurred when indicated by the evaluation above, when the symptoms commenced within the first 2 months of exposure to the drug and when those symptoms resolved upon withdrawal of the drug. Challenge, either blind or open, is unethical and potentially fatal. RegiSCAR inclusion and exclusion criteria were applied in this study as below. As all patients seen with drug-induced SCARs were taking CBZ.

Inclusion criteria

For SJS/TEN
1. CBZ was the culprit medication (established by ruling out comedication within 2 months).
2. Inpatients.
3. Widespread exanthema and more than 1% BSA skin detachment; blister formation, not acral involvement alone, with or without mucous membrane erosions.
4. SJS was defined as less than 10% of BSA skin detachment, ulceration in more than two natural cavities.
5. TEN was defined as more than 30% of BSA skin detachment and/or the presence of Nikolsky’s sign.

For DRESS
1. CBZ was the culprit medication (established by ruling out comedication within 2 months).
2. Acute onset of skin rash with fever over 38°C.
3. Enlarged lymph nodes.
4. Involvement of at least one internal organ.
5. Eosinophilia >10% or >700/μL, atypical lymphocytes, lymphopenia <4,000, lymphocytosis, thrombocytopenia.

All patients were fully informed as to the conduct and purposes of the study and signed a consent form.

Exclusion criteria

1. The following diagnoses were excluded:
   - Autoimmune bullous skin diseases
   - Erythema multiforme
   - Infection-related skin rash and bulla formation
   - Vasculitis.
2. SCAR in patients following bone marrow transplantation.
3. Unwillingness to participate.

Patients from the same hospital as the SJS/TEN/DRESS patients who had used CBZ for more than 4 months without evidence of any cutaneous reactions were recruited as controls after signing an informed consent form (controls were recruited from the Neurology and Outpatient Departments at Bach Mai Hospital).

Calculation of skin lesion and detachment areas were based on burn area estimation (Lund-Browder formula) [25]. Index-day was defined as the period from the first day of taking CBZ to the day of onset of SCAR symptoms and signs.

Genetic analysis

Blood spot cards were used to collect the blood samples from the patients. The blood spot was required to air dry for several minutes before it was placed in an envelope for transport to the laboratory. The back of the blood spot card and its envelope were labelled with the donor’s code, date and time of collection. Genomic DNA was isolated using the QIAamp DNA purification system (Qiagen, Doncaster, VIC, Australia). The combination of polymerase chain reaction and sequence-specific oligonucleotide probes with the Luminex 100xMAP flow cytometry dual laser system was then used to quantitate fluorescently labelled oligonucleotides attached to colour-coded microbeads (Sonic Clinical Institute, Sydney, NSW, Australia).

Statistical analysis

The data from the 38 subjects and 25 controls recruited into the study were used to determine statistically significant differences between groups for their clinical characteristics and HLA genotypes by using SPSS ver. 16.0 (SPSS Inc., Chicago, IL, USA). The OR for the possession of certain HLA alleles and the development of SCARs was determined. A $p$-value < 0.05 was set as the level of significance.

RESULTS

Clinical characteristics

The patient demographic data are shown in Table 1. Our cohort consisted of 38 patients comprising 20 SJS (52.6%), 7 TEN (18.4%), 8 overlap syndrome (21.1%), and 3 DRESS (7.9%). The mean age was 40.6 ± 18.7 years and a slight male preponderance was noted (male:female = 20:18). The controls (n = 25) had a mean age of 22.4 ± 13.1 years and a slight male preponderance was observed (male:female = 13:12). Involved skin lesion areas in SCARs-affected patients was 62.1% ± 24.1% of BSA, skin detachment areas of 12.3% ± 12.9% of BSA, SCORTEN scores exhibited a mean of 1.1 ± 1.0 (range, 1 to 4) and Index-days were 14.2 ± 8.3 days (median, 12.5 days). Indications for CBZ were epilepsy (34.2%), neuropathic pain (42.1%), mental disorders (18.4%) and other conditions (headache and muscular tics) (5.3%).

In our study, we also found that three patients who developed SCARs with CBZ therapy had a history of prior rashes induced by phenytoin and phenobarbital in a total of 4 exposures (60%) (Table 2). Eleven patients with SCARs had a history of herpes infection, whilst only 1 CBZ tolerant patient had a history of herpes infection (OR, 9.78; 95% CI, 1.17–81.43; $p = 0.02$).

The associations between HLA-B and CBZ-induced SCARs

When we analysed for an association between HLA-B*1502 and specific phenotypes, a strong association between HLA B*1502 and bullous skin reactions such as SJS/TEN and overlap was confirmed with an OR of 33.78 (95% CI, 7.55–151.03; $p < 0.0001$), sensitivity 91.4%, specificity 76.0%, positive predictive value 84.2% and negative predictive value 86.4%. We did not, however, observe any correlation between the presence of this allele and CBZ-induced non-bullous skin reactions (DRESS), (OR, 6.33; 95% CI, 0.48–82.74; $p = 0.1592$).

Overall, the HLA-B*1502 allele was detected in 34/38 patients (89.5%) with CBZ-induced SCARs, whilst this allele was found in only 6/25 controls (24.0%). The OR for HLA-B*1502 positivity was 26.9 (95% CI, 6.7–1074; $p < 0.001$), sensitivity 89.5%, specific-
H pylori in Vietnamese

Table 1. Clinical characteristics

| Characteristic                  | Patients (n = 38) | Control group (n = 25) |
|--------------------------------|------------------|-----------------------|
| Age (yr), mean ± SD            | 40.6 ± 18.7      | 22.4 ± 13.1           |
| Sex, male/female               | 20/18            | 13/12                 |
| SJS/Overlap/TEN/DRESS          | 20/8/7/3         | 0                     |
| Indications for carbamazepine  |                  |                       |
| Epilepsy                       | 34.2%            | 100%                  |
| Neuropathic pain               | 42.1%            | -                     |
| Mental disorders               | 18.4%            | -                     |
| Other conditions               |                  |                       |
| Headache, muscular tics        | 5.3%             | -                     |
| Index-day (day)                |                  | NA                    |
| Mean ± SD                      | 14.2 ± 8.3       |                       |
| Median (range)                 | 12.5 (2–49)      |                       |
| SJS/Overlap/TEN, median (range)| 12.0 (2–30)      | NA                    |
| DRESS, median (range)          | 16.0 (15–4)      | NA                    |
| Skin lesions (% of BSA), mean ± SD | 62.1 ± 24.1 | NA                    |
| Skin detachment (% of BSA), mean ± SD | 12.3 ± 12.9 | NA                    |
| SCORTEN, mean ± SD (range)     | 1.1 ± 1.0 (1–4)  | NA                    |
| History of herpes infection*   | 11               | 1                     |
| Mortality                      | 1 (SCORTEN 4)    | NA                    |

SD, standard deviation; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; DRESS, drug-induced hypersensitivity syndrome with rash, eosinophilia and systemic symptoms; BSA, body surface area; SCORTEN, severity-of-illness score for toxic epidermal necrolysis; NA, not applicable.

*Odds ratio, 9.78; 95% confidence interval, 1.17–81.43; p = 0.02.

Table 2. Cross-reactivity

|                                   | Reactions to aromatic agent exposures | Reactions to non-aromatic agent exposures |
|-----------------------------------|---------------------------------------|------------------------------------------|
| Patients                          | 3/5 (60%)                             | 0/4 (0%)                                 |
| Controls                          | 0/7 (0%)                              | 0/7 (0%)                                 |

DISCUSSION

In this study, we found that 34/38 SCARS patients (89.5%) possessed the HLA-B*1502 allele in comparison with 6/25 controls (24%) (OR, 26.92; 95% CI, 6.74–107.43; p <0.001). HLA-B*1502 was strongly confirmed as conferring genetic susceptibility to CBZ-induced bullous skin reactions such as SJS/TEN and overlap with OR of 33.78 (95% CI, 7.55–151.03) versus nonbullous skin reactions with OR of 6.33 (95% CI, 0.48–82.74) in Vietnamese. Although HLA-B*1502 was detected in 2 of 3 DRESS patients, this prevalence was not significantly different to its prevalence in the control group. This finding is similar to those in a number of

apallergy.org http://dx.doi.org/10.5415/apallergy.2015.5.2.68
| Patient No. | Diagnosis      | Allele 1     | Allele 2     | Serotype 1       | Serotype 2       |
|------------|---------------|--------------|--------------|-----------------|-----------------|
| 1          | SJS           | 15:02:01     | 15:18:01     | B75(15)         | B15             |
| 2          | SJS           | 15:02:01     | 15:02:01     | B75(15)         | B75(15)         |
| 3          | SJS           | 15:02:01     | 15:12        | B75(15)         | B76(15)         |
| 4          | SJS           | 15:02:01     | 40:01:01     | B75(15)         | B60(40)         |
| 5          | SJS           | 15:02:01     | 56:04:00     | B75(15)         | B56(22)         |
| 6          | SJS           | 15:02:01     | 46:01:01     | B75(15)         | B46             |
| 7          | SJS           | 15:02:01     | 39:01:01:01  | B75(15)         | B39(01)         |
| 8          | SJS           | 15:02:01     | 15:02:01     | B75(15)         | B75(15)         |
| 9          | SJS           | 15:02:01     | 15:12        | B75(15)         | B76(15)         |
| 10         | SJS           | 13:01:01     | 15:02:01     | B13             | B75(15)         |
| 11         | SJS           | 13:01:01     | 15:02:01     | B13             | B75(15)         |
| 12         | SJS           | 15:02:01     | 38:02:01     | B75(15)         | B38(16)         |
| 13         | SJS           | 15:02:01     | 35:05:01     | B75(15)         | B35             |
| 14         | SJS           | 7:05:01      | 15:02:01     | B7              | B75(15)         |
| 15         | SJS           | 15:02:01     | 54:01:00     | B75(15)         | B54(22)         |
| 16         | SJS           | 15:02:01     | 46:01:01     | B75(15)         | B46             |
| 17         | SJS           | 15:02:01     | 15:02:01     | B75(15)         | B75(15)         |
| 18         | SJS           | 15:02:01     | 55:02:01     | B75(15)         | B55(22)         |
| 19         | SJS           | 15:02:01     | 35:03:01     | B75(15)         | B35             |
| 20         | SJS           | 7:05:01      | 15:02:01     | B7              | B75(15)         |
| 21         | SJS/TEN       | 15:02:01     | 57:01:01     | B75(15)         | B57(17)         |
| 22         | SJS/TEN       | 7:05:01      | 15:02:01     | B7              | B75(15)         |
| 23         | SJS/TEN       | 13:01:01     | 15:02:01     | B13             | B75(15)         |
| 24         | SJS/TEN       | 15:02:01     | 35:05:01     | B75(15)         | B35             |
| 25         | SJS/TEN       | 7:05:01      | 15:02:01     | B7              | B75(15)         |
| 26         | SJS/TEN       | 15:02:01     | 57:01:01     | B75(15)         | B57(17)         |
| 27         | SJS/TEN       | 15:02:01     | 51:01:01     | B75(15)         | B51(15)         |
| 28         | SJS/TEN       | 15:02:01     | 15:13        | B75(15)         | B15             |
| 29         | TEN           | 13:01:01     | 46:01:01     | B13             | B46             |
| 30         | TEN           | 7:05:01      | 15:02:01     | B7              | B75(15)         |
| 31         | TEN           | 51:02:01     | 54:01:00     | B5102           | B54(22)         |
| 32         | TEN           | 15:02:01     | 40:01:01     | B75(15)         | B60(40)         |
| 33         | TEN           | 15:02:01     | 46:01:01     | B75(15)         | B46             |
| 34         | TEN           | 15:02:01     | 40:02:01     | B75(15)         | B61(40)         |
| 35         | TEN           | 38:02:01     | 51:02:01     | B38(16)         | B5102           |
| 36         | DRESS         | 15:02:01     | 15:25:01     | B75(15)         | B15             |
| 37         | DRESS         | 15:02:01     | 38:01:01     | B75(15)         | B38(16)         |
| 38         | DRESS         | 15:25:01     | 46:01:01     | B62(15)         | B46             |

Serotype 1 corresponding to Allele 1 and Serotype 2 corresponding to Allele 2. 3 homozygous patients.
SCAR, severe cutaneous adverse drug reaction; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; DRESS, drug-induced hypersensitivity syndrome with rash, eosinophilia and systemic symptoms.
*Four patients without HLA B*1502 (3 TEN, 1 DRESS).
Table 4. Correlation between HLA-B*1502 and phenotypes

| No. | Phenotypes | HLA-B*1502 positive | HLA-B*1502 negative | OR (95% CI) | p-value |
|-----|------------|---------------------|---------------------|-------------|---------|
| 1   | SJS/TEN/Overlap\(^\d\) | 32                  | 3                   | 33.78 (7.55–151.03) | <0.0001 |
| 2   | DRESS      | 2                   | 1                   | 6.33 (0.48–82.74)    | 0.1592  |
| 3   | SCARs\(^\d\) | 34                  | 4                   | 26.92 (6.74–107.43)  | <0.0001 |
| 4   | Controls   | 6                   | 19                  | -             | -       |

OR, odds ratio; CI, confidence interval; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; DRESS, drug-induced hypersensitivity syndrome with rash, eosinophilia and systemic symptoms; SCAR, severe cutaneous adverse drug reaction.

\(^\d\)Sensitivity 91.4%, specificity 76.0%, positive predictive value 84.2%, and negative predictive value 86.4%. \(^\d\)Sensitivity 89.5%, specificity 76.0%, positive predictive value 85.0%, and negative predictive value 82.6%.

Table 5. Frequencies of other HLA-B alleles in both groups

| No. | Alleles      | Patients (n = 38) | Control group (n = 25) | OR (95% CI) | p-value |
|-----|--------------|-------------------|------------------------|-------------|---------|
| 1   | HLA B* 1301  | 4                 | 3                      | 0.86 (0.18–4.23) | 1.00    |
| 2   | HLA B* 1512  | 2                 | 3                      | 0.41 (0.06–2.63) | 0.38    |
| 3   | HLA B*1513   | 1                 | 0                      | -           | -       |
| 4   | HLA B*1518   | 1                 | 0                      | -           | -       |
| 5   | HLA B* 1525  | 2                 | 1                      | 1.33 (0.11–15.53) | 1.00    |
| 6   | HLA B* 3503  | 1                 | 0                      | -           | -       |
| 7   | HLA B* 3505  | 2                 | 0                      | -           | -       |
| 8   | HLA B* 3801  | 1                 | 0                      | -           | -       |
| 9   | HLA B* 3802  | 2                 | 2                      | 0.64 (0.08–4.86) | 1.00    |
| 10  | HLA B* 3901  | 1                 | 1                      | 0.65 (0.04–10.87) | 1.00    |
| 11  | HLA B* 4001  | 2                 | 2                      | 0.64 (0.08–4.86) | 1.00    |
| 12  | HLA B* 4002  | 1                 | 0                      | -           | -       |
| 13  | HLA B* 4601  | 5                 | 9                      | 0.27 (0.08–0.94) | 0.03    |
| 14  | HLA B* 5101  | 1                 | 3                      | 0.20 (0.02–2.03) | 0.29    |
| 15  | HLA B* 5102  | 2                 | 0                      | -           | -       |
| 16  | HLA B* 5401  | 2                 | 2                      | 0.64 (0.08–4.86) | 1.00    |
| 17  | HLA B* 5502  | 1                 | 0                      | -           | -       |
| 18  | HLA B* 5604  | 1                 | 0                      | -           | -       |
| 19  | HLA B* 5701  | 2                 | 1                      | 1.33 (0.11–15.53) | 1.00    |
| 20  | HLA B* 705   | 5                 | 6                      | 0.48 (0.13–1.79) | 0.32    |
| 21  | HLA B*5801   | 0                 | 4                      | -           | -       |
| 22  | HLA B*2704   | 0                 | 2                      | -           | -       |
| 23  | HLA B*801    | 0                 | 1                      | -           | -       |
| 24  | HLA B*2706   | 0                 | 1                      | -           | -       |
| 25  | HLA B*3905   | 0                 | 1                      | -           | -       |
| 26  | HLA B*4403   | 0                 | 1                      | -           | -       |
| 27  | HLA B*1501   | 0                 | 1                      | -           | -       |

OR, odds ratio; CI, confidence interval.
previous studies in Asians with different ancestries such as Han Chinese [3, 4, 6–9], Thais [4, 10, 27], Malays [4, 12], Indians [11] and Singaporeans [4, 13]. Vietnam is similar to other countries in Asia then, in that the presence of HLA-B*1502 strongly predisposes to the development of immunologically-induced bullous skin rashes due to CBZ hypersensitivity. In our study, however, we observed a much higher prevalence of HLA-B*1502 in the CBZ-tolerant group compared with that observed in any other previous study (11.9% [10] and 18% [27] in two Thai studies, 8% in central Han Chinese [7] and 13.75% in southern Chinese Hans [6]. This finding is likely to be due to the high prevalence overall of HLA-B*1502 in our population (13.5%), although the smaller number of controls compared with our patient group might be considered as a limitation of our study and the inclusion of a larger number of controls in any future study may clarify the significance of our initial observation.

In regard to HLA-B*4601, the prevalence of this variant is significantly different between patients and controls (OR, 0.27; 95% CI, 0.08–0.94; p = 0.03), being found more commonly in the controls. This suggests that the presence of this allele may be protective against the development of CBZ-induced SCARs in Vietnamese. In keeping with our finding, Alfirevic et al. [28] noted in Caucasians that the presence of the HLA-B*0702 allele appears to be protective in terms of developing CBZ hypersensitivity while HLA-B*4001 and HLA-A*2402 have been demonstrated to be protective markers in Asian populations [29]. However, HLA-B*4601 is the second commonest allele (11.5%) among HLA-B genes in the Vietnamese population [18]. It follows therefore that the lower prevalence of HLA-B*1502 in the controls would be likely compensated for by a higher prevalence of HLA-B*4601. Therefore, the supposition that the presence of the HLA-B*4601 allele might be protective needs to be confirmed in a study with a larger number of controls.

We did not find an association between the presence of HLA-B*1511 and the development of SJS/TEN, as has been reported in other Asians [26]. In addition, this allele was not found in the study of 170 Kinh Vietnamese conducted by Hoa et al. [18]. Thus it seems reasonable to conclude that HLA-B*1511 is not a genetic risk factor for CBZ-induced SCARs in Vietnamese.

Cross-reactivity exists frequently between CBZ, phenytoin and phenobarbital and both phenytoin and phenobarbital in a total of 4 exposures (60%) (Table 2). This finding emphasizes the cross-reactivity risks for patients treated with any drug in the aromatic anticonvulsant group and consequently, the use of cross-reactive drugs should be avoided in our population. Moreover, work by Hu et al. [35] (albeit their patients suffered mild cutaneous reactions) indicates that patients with HLA-B*1502 should also avoid newer anticonvulsants such as oxcarbazepine. Conversely, when our controls tolerated CBZ, they also tolerated other anticonvulsants such as phenytoin, phenobarbital, oxcarbazepine and sodium valproate. Our finding also stressed that no SCARs-induced CBZ patient (0/4) had previous reactions to nonaromatic anticonvulsant drugs such as valproate, topiramate or gabapentin. Our clinical recommendation is that patients who have previously developed rashes to CBZ should be treated with nonaromatic anticonvulsant agents.

The age range of those affected by SCARs may reflect the age range wherein CBZ use is more likely rather than implying that the age of the patient predisposes to the development of these conditions; however, our data suggest that there is an increased risk of developing SCARs in middle age compared to the first few decades of life (mean age 40.6 ± 18.7 in the patient group vs. 22.4 ± 13.1 in the control group). In keeping with our finding, Seitz et al. [31] reported that the mean age of 36 patients with anticonvulsant hypersensitivity was 59 years (range, 13–92 years) and the mean age in 24 patients reported by Kim et al. [16] was 52.1 ± 15.1 years. Alvestad et al. [36] also concluded that the number of CBZ-induced skin rashes significantly increased with age (6% [10/172] in the group under 16 years, 12% [33/270] in those aged from 16–49 years and 19% [10/53] in those aged over 50 years, p = 0.012). Generally, however, it seems to be that adverse drug reactions occurring in inpatients are more prevalent in the older age group compared with younger patients [37]. Irrespective of age, possession of the HLA-B*1502 genotype is strongly associated with the occurrence of SCARs in our patients.

Our data showed a slight male preponderance in the group with SCARs (male:female = 20:18). This finding was also noted by Kim et al. [16] and Zhang et al. [8]. However, generally, in studies based on larger sample sizes, CBZ-induced skin rashes were significantly increased in females. In their review of 137 Han Chinese patients with anticonvulsant hypersensitivity, Wang et al. [33] indi-
cated that development of a rash was nearly twice as frequent in females (OR, 1.84; 95% CI, 1.32–2.60; \( p < 0.001 \)). Further, Alvestad et al. [36] reported that CBZ-induced rash occurred more commonly in females (19% vs. 8%, respectively, \( p < 0.001 \)) and they postulated that this finding results from the impact of sex hormones on T-cell populations as CBZ hypersensitivity is an immunologically T-cell-mediated reaction. This female preponderance remains to be confirmed across the clinical spectrum of CBZ hypersensitivity.

An association between SCARs and herpes infection has been described previously and confirmed serologically [38-41]. Our data suggest an association may exist in our population with OR, 9.78 (95% CI, 1.17–81.43; \( p = 0.02 \)) when comparing patients and controls. Historically, a number of patients had suffered from herpes infection. Some of them were tested for herpes simplex virus type 1 (HSV1) and herpes simplex virus type 2 (HSV2) and were IgG positive. Oskay et al. [39] concluded in their study that anticonvulsant hypersensitivity was accompanied by serological evidence of human herpes virus (HHV-6 and HHV-7) infection and reactivation but had no significant association with HSV infection. Unfortunately, in our hospital we are not able to identify the human herpes viruses type 6 and 7 and therefore cannot confirm our clinical findings serologically. Most studies, however, suggest human herpes virus type 6 is the likely culprit of anticonvulsant hypersensitivity syndrome [40].

Lastly, the majority of our patients developed their first symptoms early during therapy with an index-day median of 12.5 days (range, 2–49 days). Chong et al. [13] reported that the median time span in their group of CBZ-induced SJS/TEN sufferers was 12 days (range, 11–13 days) and 16 days (range, 10–37 days) in DRESS patients. In our study, we observed that the first symptom appeared later at a median of 16 days (range, 15–49 days) in the three patients with DRESS compared with the group with SJS/TEN and overlap with a median of 12 days (range, 2–30 days). Studies conducted by Kim et al. [16] in Koreans and by Chong et al. [13] in Singaporeans have documented similar findings to those in our study.

In future studies, we would like to be able to clarify any association in our patients between herpes virus infection and SCARs, identify the type of herpes infection, and confirm this serologically.

Regarding the limitations of this study, we also realize that additional data will be required to determine whether gender and age play a role in susceptibility to SCARs in our population. Having an age-matched control group and expanding the control group numbers would be desirable in any future study, as these improvements might allow us to resolve whether the high prevalence of HLA-B*1502 in our controls is due to the high prevalence of this allele in the Vietnamese population in general.

HLA-A*3101, the presence of which has been associated with the development of CBZ-induced hypersensitivity reactions in Caucasians [42], was not evaluated in this study because HLA-A*3101 is quite rare in Vietnamese (2.1%) [18] and therefore the number of patients we were able to evaluate in this study precluded searching for such an association. Future studies searching for this association in larger numbers of patients will be required to determine whether there exists an association between the presence of HLA-A*3101 and the development of SCARs in Vietnamese.

In conclusion, we have demonstrated that Vietnamese patients are at greater risk of developing SCARs from anticonvulsant therapies and this finding is in keeping with studies from other Asian countries. Our study indicates that Vietnamese patients, therefore, should have their HLA genotype determined prior to be planned commencement of therapy with CBZ. As genotype confers this increased risk, our findings have implications for those of Vietnamese ethnicity living elsewhere in the world. To reduce the mortality and morbidity associated with these severe drug-induced reactions we propose that Vietnamese patients, here or overseas, have their HLA genotype determined, prior to the planned commencement of any of the aromatic anticonvulsants and if they are found to possess HLA-B*1502, they should not be treated with CBZ, phenytoin, phenobarbital or oxcarbazepine or any aromatic anticonvulsants developed in the future.

ACKNOWLEDGEMENTS

The authors wish to thank the Hoc Mai Foundation, The University of Sydney, Sydney, Australia, for funding this study. We are grateful to our colleagues at the Center of Allergology and Clinical Immunology and in the Departments of Neurology and Outpatients at Bach Mai Hospital, Hanoi, Vietnam and especially thankful to our patients and case controls and their families who helped us complete this work.
REFERENCES

1. Lim KS, Kwan P, Tan CT. Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review. Neurology Asia 2008;13:15-21.

2. Fernando SL, Broadfoot AJ. Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening. CMAJ 2010;182:476-80.

3. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.

4. Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Loihitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 2013;149:1025-32.

5. Sun D, Yu CH, Liu ZS, He XL, Hu JS, Wu GF, Mao B, Wu SH, Xiang HH. Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China. J Huazhong Univ Sci Technolog Med Sci 2014;34:146-50.

6. Wang Q, Zhou JQ, Zhou LM, Chen ZY, Fang ZY, Chen SD, Yang LB, Cai XD, Dai QL, Hong H, Wang HK. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure 2011;20:446-8.

7. Wu XT, Hu FY, An DM, Yan B, Jiang X, Kwan P, Stefan H, Zhou D. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Epilepsy Behav 2010;19:405-8.

8. Zhang Y, Wang J, Zhao LM, Peng W, Shen GQ, Xue L, Zheng XX, He XJ, Gong CY, Miao LY. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol 2011;67:885-7.

9. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MH. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007;48:1015-8.

10. Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Chen P, Lin SY, Chen WH, Konyakornprasertsar U, Auwichayapat N, Pavakul K, Kulkantrakorn K, Choonhakarn C, Phonhimanhan S, Piyatrakul N, Aungaree T, Pongpakdee S, Yodnopaglaw P. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010;51:926-30.

11. Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB, Dave DM, Goyal RK. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009;75:579-82.

12. Chang CC, Too CL, Murad S, Hussein SH. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol 2011;50:221-4.

13. Chong KW, Chan DW, Cheung YB, Ching LK, Hie SL, Thomas T, Ling S, Tan EC. Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore. Arch Dis Child 2014;99:581-4.

14. Hung SI, Chung WH. Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 2013;80:1621.

15. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawai da J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R; JSAR research group. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008;9:1617-22.

16. Kim SH, Lee KW, Song WJ, Kim SH, Jee YK, Lee SM, Kang HR, Park HW, Cho SH, Park SH, Min KU, Chang YS. Adverse Drug Reaction Research Group in Korea. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res 2011;97:190-7.

17. Kim SH, Ye YM, Palikhe NS, Kim JE, Park HS. Genetic and ethnic risk factors associated with drug hypersensitivity. Curr Opin Allergy Clin Immunol 2010;10:280-90.

18. Hoa BK, Hang NT, Kashiwase K, Ohashi J, Lien LT, Horie T, Shojima J, Hiji kata M, Sakurada S, Satake M, Tokunaga K, Sasazuki T, Keicho N. HLA-A, -B, -C, -DRB1 and -DQB1 alleles and haplotypes in the Kinh population in Vietnam. Tissue Antigens 2008;71:127-34.

19. Sekula P, Liss Y, Davidovici B, Dunant A, Roujeau JC, Kardaun S, Naldi L, Schumacher M, Mockenhaupt M. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res 2011;32:237-45.

20. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.

21. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, Tai CT, Wu SL, Lu CH, Hsu YC, Yu HY, Ro LS, Lu CT, Chu CC, Tsai JI, Su YH, Lan SH, Sung SF, Lin SY, Chung HP, Huang LC, Chen YJ, Tsai PJ, Liao HT, Lin YH, Chen CH, Chung WH, Hung SI, Wu JY, Chang CF, Chen L, Chen YT, Shen CY, Taiwan SJS Consortium. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011;364:1126-33.
22. Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008;9:1543-6.

23. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.

24. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005;209:123-9.

25. Yu CY, Lin CH, Yang YH. Human body surface area database and estimation formula. Burns 2010;36:616-29.

26. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R. JSAR research group. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010;51:2461-5.

27. Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, Kangwanshiratada O, Hirankarn N, Suphapeetiporn K, Shotelersuk V. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008;49:2087-91.

28. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pir-mohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006;7:813-8.

29. Grover S, Kukreti R. HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet Genomics 2014;24:94-112.

30. Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res 2008;80:194-200.

31. Seitz CS, Pfeuffer P, Raith P, Brocker EB, Trautmann A. Anticonvulsant hypersensitivity syndrome: cross-reactivity with tricyclic antidepressant agents. Ann Allergy Asthma Immunol 2006;97:698-702.

32. Wang Q, Lang SY, Shi XB, Tian HJ, Wang RF, Yang F. Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population. Seizure 2010;19:562-6.

33. Sierra NM, Garcia B, Marco J, Plaza S, Hidalgo F, Bermejo T. Cross Hypersensitivity Syndrome between phenytoin and carbamazepine. Pharm World Sci 2005;27:170-4.

34. Hu FY, Wu XT, An DM, Yan B, Stefan H, Zhou D. Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population. Seizure 2011;20:160-2.

35. Sullivan JR, Shear NH. Drug eruptions and other adverse drug effects in aged skin. Clin Geriatr Med 2002;18:21-42.

36. Watanabe H, Daibata M, Tohyama M, Batchelor J, Hashimoto K, Iijima M. Chromosomal integration of human herpesvirus 6 DNA in anticonvulsant hypersensitivity syndrome. Br J Dermatol 2008;158:640-2.

37. Kano Y, Inaoka M, Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol 2004;140:183-8.

38. Descamps V, Bouscarat F, Laglenne S, Aslangul E, Veber B, Descamps D, Seraux JL, Grange MJ, Grossin M, Navratil E, Cricke B, Belaich S. Human herpesvirus 6 infection associated with anticonvulsant hypersensitivity syndrome and reactive haemophagocytic syndrome. Br J Dermatol 1997;137:605-8.

39. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kaspersaviciute D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PI, Chinthapalli K, Molokhia M, Johnson MR, O’Connor GD, Chaila E, Alhusaini S, Shinnan KV, Radtke RA, Heinzen EL, Walley N, Pandolfo M, Pichler W, Park BK, Depondt C, Sisodya SM, Goldstein DB, Deloukas P, Delany N, Cavalleri GL, Pir-mohamed M. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134-43.